Is CryoCell International Stock a Good Investment?
CryoCell International Investment Advice | CCEL |
- Examine CryoCell International's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research CryoCell International's leadership team and their track record. Good management can help CryoCell International navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact CryoCell International's business and its evolving consumer preferences.
- Compare CryoCell International's performance and market position to its competitors. Analyze how CryoCell International is positioned in terms of product offerings, innovation, and market share.
- Check if CryoCell International pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about CryoCell International's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in CryoCell International stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if CryoCell International is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine CryoCell International Stock
Researching CryoCell International's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 48.0% of the company shares are held by company insiders. The company last dividend was issued on the 14th of February 2025.
To determine if CryoCell International is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CryoCell International's research are outlined below:
| CryoCell International generated a negative expected return over the last 90 days | |
| CryoCell International has high historical volatility and very poor performance | |
| CryoCell International currently holds 4.45 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. CryoCell International has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about CryoCell International's use of debt, we should always consider it together with its cash and equity. | |
| About 48.0% of CryoCell International shares are held by company insiders | |
| On 28th of February 2025 CryoCell International paid $ 0.25 per share dividend to its current shareholders | |
| Latest headline from news.google.com: Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024 - Financial Content |
CryoCell International uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CryoCell International. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CryoCell International's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact CryoCell International's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises CryoCell International's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-07-15 | 2024-05-31 | 0.04 | 0.08 | 0.04 | 100 | ||
2024-04-15 | 2024-02-29 | -0.02 | 0.07 | 0.09 | 450 | ||
2024-10-15 | 2024-08-31 | 0.02 | 0.13 | 0.11 | 550 | ||
2023-07-14 | 2023-05-31 | -0.08 | 0.03 | 0.11 | 137 | ||
2007-02-28 | 2006-11-30 | 0.03 | -0.08 | -0.11 | 366 | ||
2023-02-28 | 2022-11-30 | -0.02 | 0.1 | 0.12 | 600 | ||
2006-10-16 | 2006-08-31 | 0.03 | -0.09 | -0.12 | 400 | ||
2023-04-21 | 2023-02-28 | -0.04 | 0.09 | 0.13 | 325 |
Know CryoCell International's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CryoCell International is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CryoCell International backward and forwards among themselves. CryoCell International's institutional investor refers to the entity that pools money to purchase CryoCell International's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-12-31 | 13.6 K | Ubs Group Ag | 2024-12-31 | 3.1 K | Advisor Group Holdings, Inc. | 2024-12-31 | 2 K | Tower Research Capital Llc | 2024-12-31 | 1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 601 | Sbi Securities Co Ltd | 2024-12-31 | 105 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 100.0 | Bank Of America Corp | 2024-12-31 | 33.0 | Jpmorgan Chase & Co | 2024-12-31 | 11.0 | Hamilton Lane Advisors Llc | 2024-12-31 | 409.7 K | Sfi Advisors, Llc | 2024-12-31 | 165.3 K |
CryoCell International's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.56 M.Market Cap |
|
CryoCell International's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.07 | 0.08 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | (0.04) | (0.04) |
Determining CryoCell International's profitability involves analyzing its financial statements and using various financial metrics to determine if CryoCell International is a good buy. For example, gross profit margin measures CryoCell International's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CryoCell International's profitability and make more informed investment decisions.
Evaluate CryoCell International's management efficiency
CryoCell International has return on total asset (ROA) of 0.0376 % which means that it generated a profit of $0.0376 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.292 %, meaning that it created $1.292 on every $100 dollars invested by stockholders. CryoCell International's management efficiency ratios could be used to measure how well CryoCell International manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CryoCell International's Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.08 this year, although the value of Return On Equity will most likely fall to (0.04). At this time, CryoCell International's Other Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 0.01 this year, although the value of Net Tangible Assets will most likely fall to (17.6 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.87) | (1.78) | |
| Tangible Book Value Per Share | (2.27) | (2.16) | |
| Enterprise Value Over EBITDA | 60.12 | 57.11 | |
| Price Book Value Ratio | (6.13) | (5.83) | |
| Enterprise Value Multiple | 60.12 | 57.11 | |
| Price Fair Value | (6.13) | (5.83) | |
| Enterprise Value | 85.5 M | 81.3 M |
CryoCell International benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Basic technical analysis of CryoCell Stock
As of the 26th of March, CryoCell International shows the Standard Deviation of 3.72, risk adjusted performance of (0.04), and Mean Deviation of 2.68. CryoCell International technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CryoCell International market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if CryoCell International is priced correctly, providing market reflects its regular price of 6.38 per share. Given that CryoCell International has information ratio of (0.06), we suggest you to validate CryoCell International's prevailing market performance to make sure the company can sustain itself at a future point.CryoCell International's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CryoCell International insiders, such as employees or executives, is commonly permitted as long as it does not rely on CryoCell International's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CryoCell International insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CryoCell International's Outstanding Corporate Bonds
CryoCell International issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CryoCell International uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CryoCell bonds can be classified according to their maturity, which is the date when CryoCell International has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand CryoCell International's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing CryoCell International's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | (1,670) | |||
| Standard Deviation | 3.72 | |||
| Variance | 13.82 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 23.13 | |||
| Value At Risk | (4.60) | |||
| Potential Upside | 5.4 | |||
| Skewness | (0.75) | |||
| Kurtosis | 3.24 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | (1,670) | |||
| Standard Deviation | 3.72 | |||
| Variance | 13.82 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 23.13 | |||
| Value At Risk | (4.60) | |||
| Potential Upside | 5.4 | |||
| Skewness | (0.75) | |||
| Kurtosis | 3.24 |
Consider CryoCell International's intraday indicators
CryoCell International intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CryoCell International stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CryoCell International Corporate Filings
10K | 28th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 23rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 27th of December 2024 Other Reports | ViewVerify | |
| 12th of November 2024 Other Reports | ViewVerify |
CryoCell Stock media impact
Far too much social signal, news, headlines, and media speculation about CryoCell International that are available to investors today. That information is available publicly through CryoCell media outlets and privately through word of mouth or via CryoCell internal channels. However, regardless of the origin, that massive amount of CryoCell data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CryoCell International news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CryoCell International relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CryoCell International's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CryoCell International alpha.
CryoCell International Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards CryoCell International can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
CryoCell International Corporate Executives
Elected by the shareholders, the CryoCell International's board of directors comprises two types of representatives: CryoCell International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CryoCell. The board's role is to monitor CryoCell International's management team and ensure that shareholders' interests are well served. CryoCell International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CryoCell International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jill Taymans | CFO and VP of Fin. | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Dividend Share 0.25 | Earnings Share 0.05 | Revenue Per Share | Quarterly Revenue Growth 0.019 |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between CryoCell International's value and its price, as these two are different measures arrived at by various means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.